Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Forte Biosciences, Inc. (FBRX : NSDQ)

• Company Description    Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $12.19 Daily Weekly Monthly 20 Day Moving Average: 95,914 shares Shares Outstanding: 12.43 (millions) Market Capitalization: $151.56 (millions) Beta: 3.03 52 Week High: $28.68 52 Week Low: $4.11 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.55% -18.06% 12 Week 4.82% -0.56% Year To Date -46.32% -53.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3060 PEGASUS PARK DRIVE BUILDING 6 - DALLAS,TX 75247 USA ph: 310-618-6994 fax: - investors@fortebiorx.com http://www.fortebiorx.com

• General Corporate Information    Officers Paul A. Wagner - Chairman and Chief Executive Officer Antony Riley - Chief Financial Officer Scott Brun - Director Barbara K. Finck - Director David Gryska - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 34962G208 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 12.43 Most Recent Split Date: 8.00 (0.04:1) Beta: 3.03 Market Capitalization: $151.56 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.89 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.52 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 85.78% vs. Previous Quarter: 29.93% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -85.38 03/31/25 - -149.15 ROA 09/30/25 - - 06/30/25 - -72.34 03/31/25 - -114.25 Current Ratio 09/30/25 - - 06/30/25 - 11.74 03/31/25 - 5.22 Quick Ratio 09/30/25 - - 06/30/25 - 11.74 03/31/25 - 5.22 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 8.03 03/31/25 - 5.84 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©